[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641682":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":55,"locations":61,"responsibleParty":110,"collaborators":32,"id":112,"slug":32,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":113,"sex":119,"minAge":120,"maxAge":32,"enrollmentInfo":121,"targetDuration":32,"studyType":124,"phases":125,"briefSummary":127,"conditions":128,"keywords":137,"overallStatus":64,"whyStopped":32,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Revolution Medicines, Inc.","INDUSTRY",[8,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: zoldonrasib + chemotherapy","EXPERIMENTAL","study drug in combination with Investigator choice chemotherapy (mFFX or GnP)",[13,14,15,16,17,18,19],"Drug: Zoldonrasib","Drug: Oxaliplatin","Drug: Leucovorin (Calcium Folinate)","Drug: 5-Fluorouracil","Drug: Irinotecan","Drug: Gemcitabine (GEM)","Drug: Nab-paclitaxel",{"label":21,"type":22,"description":23,"interventionNames":24},"Arm B: placebo + chemotherapy","PLACEBO_COMPARATOR","placebo in combination with Investigator choice chemotherapy (mFFX or GnP)",[25,14,15,16,17,18,19],"Drug: Placebo",[27,33,36,40,43,46,49,52],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Zoldonrasib","oral tablets",[9],null,{"type":28,"name":34,"description":30,"armGroupLabels":35,"otherNames":32},"Placebo",[21],{"type":28,"name":37,"description":38,"armGroupLabels":39,"otherNames":32},"Oxaliplatin","IV infusion",[9,21],{"type":28,"name":41,"description":38,"armGroupLabels":42,"otherNames":32},"Leucovorin (Calcium Folinate)",[9,21],{"type":28,"name":44,"description":38,"armGroupLabels":45,"otherNames":32},"5-Fluorouracil",[9,21],{"type":28,"name":47,"description":38,"armGroupLabels":48,"otherNames":32},"Irinotecan",[9,21],{"type":28,"name":50,"description":38,"armGroupLabels":51,"otherNames":32},"Gemcitabine (GEM)",[9,21],{"type":28,"name":53,"description":38,"armGroupLabels":54,"otherNames":32},"Nab-paclitaxel",[9,21],[56],{"name":57,"role":58,"phone":59,"phoneExt":32,"email":60},"Revolution Medicines Study Director","CONTACT","1-844-2-REVMED","medinfo@revmed.com",[62,80,95],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Moffitt Cancer Center","RECRUITING","Tampa","Florida","33612","United States",{"type":70,"coordinates":71},"Point",[72,73],-82.45843,27.94752,{"lat":73,"lon":72},[76],{"name":77,"role":58,"phone":78,"phoneExt":32,"email":79},"Kim","813-745-3691","Cheyenne.Schneider@moffitt.org",{"facility":81,"status":64,"city":82,"state":83,"zip":84,"country":68,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Piedmont Healthcare","Atlanta","Georgia","30318",{"type":70,"coordinates":86},[87,88],-84.38798,33.749,{"lat":88,"lon":87},[91],{"name":92,"role":58,"phone":93,"phoneExt":32,"email":94},"Mieri","404-425-1777","Takiyyah.Hamilton@piedmont.org",{"facility":96,"status":64,"city":97,"state":98,"zip":99,"country":68,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Johns Hopkins University","Baltimore","Maryland","21287",{"type":70,"coordinates":101},[102,103],-76.61219,39.29038,{"lat":103,"lon":102},[106],{"name":107,"role":58,"phone":108,"phoneExt":32,"email":109},"Apostol","410-502-7484","giclinicaltrials@jhmi.edu",{"type":111,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100641682",false,"NCT07621718","Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )","RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma","RASolute 305","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed pancreatic adenocarcinoma.\n* Diagnosis of metastatic disease ≤ 6 weeks prior to screening.\n* Documented KRAS G12D mutation status.\n* Measurable disease per RECIST v1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior treatment with systemic anticancer therapy in unresectable locally advanced or metastatic setting.\n* Prior systemic RAS-targeted therapy any time prior to randomization.\n* Presence of other known driver mutations with approved targeted therapies\n* Active or known history of untreated central nervous system metastatic disease.\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.","ALL","18 Years",{"count":122,"type":123},670,"ESTIMATED","INTERVENTIONAL",[126],"PHASE3","The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.",[129,130,131,132,133,134,135,136],"Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Pancreatic Adenosquamous Carcinoma",[129,131,138,139,140,141,130,134,136,135],"Pancreatic Ductal Adenocarcinoma","RAS","KRAS","RAS Mutation","2026-06-12",{"date":144,"type":145},"2026-06-16","ACTUAL",{"date":147,"type":145},"2026-05-22",{"date":149,"type":123},"2030-04-22",{"name":5,"class":6},3]